Cited by 401Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index.

Protein phosphatase 2A: a target for anticancer therapy

Open access

Perrotti, Danilo, Neviani, Paolo·2013·The Lancet Oncology

DOI 10.1016/s1470-2045(12)70558-2PMC PMC3913484

Open this paper in CoChat — free account

Abstract

Protein phosphatase 2A (PP2A), one of the main serine-threonine phosphatases in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven intracellular signalling pathways. Unrestrained activation of oncogenic kinases together with inhibition of tumour suppressors is often required for development of cancer. PP2A has been shown to be genetically altered or functionally inactivated in many solid cancers and leukaemias, and is therefore a tumour suppressor. For example, the phosphatase activity of PP2A is suppressed in chronic myeloid leukaemia and other malignancies characterised by aberrant activity of oncogenic kinases. Preclinical studies show that pharmacological restoration of PP2A tumour-suppressor activity by PP2A-activating drugs (eg, FTY720) effectively antagonises cancer development and progression. Here, we discuss PP2A as a druggable tumour suppressor in view of the possible introduction of PP2A-activating drugs into anticancer therapeutic protocols.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70558-2

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma
Omar, H. A., Chou, C.-C., Berman-Booty, L. D., Ma, Y., Hung, J., Wang, D.-S., Kogure, T., Patel, T. C., Terracciano, L., Muthusamy, N., et al. (2011) · Hepatology · doi:10.1002/hep.24293 · Cited by 74
Retracted
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,181
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,028
Bcl-2 family proteins and cancer
Yip, K. W., & Reed, J. C. (2008) · Oncogene · doi:10.1038/onc.2008.307 · Cited by 913
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 608
Self-citation
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H. C., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 481
Self-citation

Show all 103 references

Sorted by citations

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Zhai, B., Hu, F., Jiang, X. L., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1043 · Cited by 286
Platelets reduce anoikis and promote metastasis by activating YAP1 signaling
Haemmerle, M., Taylor, M., Gutschner, T., Pradeep, S., Cho, M. S., Sheng, J., Lyons, Y., Nagaraja, A. S., Dood, R. L., Wen, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00411-z · Cited by 274
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G. J., Dorrance, A. M., Paisie, C. A., Eiring, A. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68951 · Cited by 227
Self-citation
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Huwiler, A., & Zangemeister‐Wittke, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.001 · Cited by 227
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S. R., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.022 · Cited by 211
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
Therapeutic targeting of PP2A
O’Connor, C. M., Perl, A. L., Léonard, D., Sangodkar, J., & Narla, G. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 185
The emerging role of FTY720 (Fingolimod) in cancer treatment
White, C., Alshaker, H. A., Cooper, C., Winkler, M. H., & Pchejetski, D. (2016) · Oncotarget · doi:10.18632/oncotarget.7145 · Cited by 175
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
Kaboli, P. J., Salimian, F., Aghapour, S., Xiang, S., Zhao, Q., Li, M., Wu, X., Du, F., Zhao, Y., Shen, J., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104806 · Cited by 159
Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
Walker, C. J., Oaks, J. J., Santhanam, R., Neviani, P., Harb, J. G., Ferenchak, G. J., Ellis, J. J., Landesman, Y., Eisfeld, A., Gabrail, N., et al. (2013) · Blood · doi:10.1182/blood-2013-04-495374 · Cited by 143
Self-citation
The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time?
Sapio, L., Gallo, M., Illiano, M., Chiosi, E., Naviglio, D., Spina, A., & Naviglio, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25650 · Cited by 144
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
Stanford, S. M., & Bottini, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00618-w · Cited by 139
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Chung, V. M., Mansfield, A. S., Braiteh, F., Richards, D., Durivage, H. J., Ungerleider, R. S., Johnson, F., & Kovach, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2299 · Cited by 129
Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells
Yamada, S., Tsukamoto, S., Huang, Y., Makio, A., Kumazoe, M., Yamashita, S., & Tachibana, H. (2016) · Scientific Reports · doi:10.1038/srep19225 · Cited by 127
Targeting PP2A in cancer: Combination therapies
Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.020 · Cited by 130
B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability
Houge, G., Haesen, D., Vissers, L. E. L. M., Mehta, S., Parker, M. J., Wright, M., Vogt, J., McKee, S., Tolmie, J. L., Cordeiro, N., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79860 · Cited by 124
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization
Liu, Z., Yoshimi, A., Wang, J., Cho, H., Chun-Wei Lee, S., Ki, M., Bitner, L., Chu, T., Shah, H., Liu, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1330 · Cited by 118
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies
Oaks, J. J., Santhanam, R., Walker, C. J., Roof, S. R., Harb, J. G., Ferenchak, G. J., Eisfeld, A., Brocklyn, J. R. V., Briesewitz, R., Saddoughi, S. A., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492181 · Cited by 111
Self-citation
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 108
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
Liu, C., Hung, M., Wang, D., Chu, P., Su, J.-C., Teng, T.-H., Huang, C., Chao, T.-T., Wang, C., Shiau, C., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0431-9 · Cited by 105
MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer
Zhang, Y., Talmon, G., & Wang, J. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.200 · Cited by 104
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer
Hait, N. C., Avni, D., Yamada, A., Nagahashi, M., Aoyagi, T., Aoki, H., Dumur, C. I., Zelenko, Z., Gallagher, E. J., LeRoith, D., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.16 · Cited by 105
Mechanisms of microcystin-LR-induced cytoskeletal disruption in animal cells
Zhou, M., Tu, W.-W., & Xu, J. (2015) · Toxicon · doi:10.1016/j.toxicon.2015.05.005 · Cited by 107
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
Rodgers, S. J., Ferguson, D. T., Mitchell, C. A., & Ooms, L. M. (2017) · Bioscience Reports · doi:10.1042/bsr20160432 · Cited by 105
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Rincón, R., Cristóbal, I., Zazo, S., Arpí, O., Menéndez, S., Manso, R., Lluch, A. M., Eroles, P., Rovira, A., Albanell, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3012 · Cited by 101
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β–mediated colitis
Mao, L., Kitani, A., Hiejima, E., Montgomery-Recht, K., Zhou, W., Fuss, I. J., Wiestner, A. U., & Strober, W. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128322 · Cited by 101
Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling
Gao, S., Duan, C., Gao, G., Wang, X., & Yang, H. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.006 · Cited by 98
FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells
Zhong, Y., Tian, F., Ma, H., Wang, H., Yang, W., Liu, Z., & Liao, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118077 · Cited by 100
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
Liu, H., Gu, Y., Wang, H., Yin, J., Zheng, G., Zhang, Z., Lu, M., Wang, C., & He, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3818 · Cited by 96
Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Cyanobacterial Toxins of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in Drinking Water
Miller, T. R., Beversdorf, L. J., Weirich, C. A., & Bartlett, S. L. (2017) · Marine Drugs · doi:10.3390/md15060160 · Cited by 97
Genomic regulation of transcription and RNA processing by the multitasking Integrator complex
Welsh, S. A., & Gardini, A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00534-2 · Cited by 92
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
Senapati, J., Jabbour, E. J., Kantarjian, H. M., & Short, N. J. (2022) · Leukemia · doi:10.1038/s41375-022-01736-5 · Cited by 95
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer
Álvarez‐Fernández, M., Sanz‐Flores, M., Sanz‐Castillo, B., Salazar‐Roa, M., Partida, D., Zapatero‐Solana, E., Ali, H. R., Manchado, E., Lowe, S. W., VanArsdale, T. L., et al. (2017) · Cell Death and Differentiation · doi:10.1038/s41418-017-0024-0 · Cited by 82
Robust inference of kinase activity using functional networks
Yılmaz, S., Ayati, M., Schlatzer, D., Çiçek, A. E., Chance, M. R., & Koyutürk, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21211-6 · Cited by 86
Circular MTHFD2L RNA-encoded CM-248aa inhibits gastric cancer progression by targeting the SET-PP2A interaction
Liu, H., Fang, D., Zhang, C., Zhao, Z., Liu, Y., Zhao, S., Zhang, N., & Xu, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.013 · Cited by 82
Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer
Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0724 · Cited by 78
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
PP2A: The Wolf in Sheep’s Clothing?
Bailey‐Whyte, M., & Kiely, P. (2015) · Cancers · doi:10.3390/cancers7020648 · Cited by 82
PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis
Zhou, X., Updegraff, B. L., Guo, Y., Peyton, M., Girard, L., Larsen, J. E., Xie, X., Zhou, Y., Hwang, T. H., Xie, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1267-t · Cited by 75
Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex
He, X., Li, M., Yu, H., Liu, G., Wang, N., Yin, C., Tu, Q., Narla, G., Tao, Y., Cheng, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000803 · Cited by 76
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
“1A), these PP2A inhibitor proteins (PAIPs hereafter) (4) have been found to suppress PP2A function toward its phosphosubstrates (3, 4, 22, 23).”
Background
The basic biology of PP2A in hematologic cells and malignancies
Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., & Janssens, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00347 · Cited by 73
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands
De, P. K., Carlson, J. H., Leyland-Jones, B. R., & Dey, N. (2014) · Oncotarget · doi:10.18632/oncotarget.2127 · Cited by 72
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
Dominant Suppression of Inflammation via Targeted Mutation of the mRNA Destabilizing Protein Tristetraprolin
Ross, E. A., Smallie, T., Ding, Q., O’Neil, J. D., Cunliffe, H. E., Tang, T., Rosner, D. R., Klevernic, I. V., Morrice, N. A., Monaco, C. G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402826 · Cited by 70
Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
Pippa, R., Dominguez, A., Christensen, D. J., Moreno–Miralles, I., Blanco‐Prieto, M. J., Vitek, M. P., & Odero, M. D. (2014) · Leukemia · doi:10.1038/leu.2014.141 · Cited by 73
Tumor Necrosis Factor-α (TNFα)-induced Ceramide Generation via Ceramide Synthases Regulates Loss of Focal Adhesion Kinase (FAK) and Programmed Cell Death
Hernandez‐Corbacho, M. J., Canals, D., Adada, M. M., Liu, M., Senkal, C. E., Yi, J. K., Mao, C., Luberto, C., Hannun, Y. A., & Obeid, L. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.658658 · Cited by 71
Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
Taleski, G., & Sontag, E. (2017) · FEBS Letters · doi:10.1002/1873-3468.12907 · Cited by 71
NNMT depletion contributes to liver cancer cell survival by enhancing autophagy under nutrient starvation
Shin, J. H., Park, C. W., Yoon, G., Hong, S. M., & Choi, K. Y. (2018) · Oncogenesis · doi:10.1038/s41389-018-0064-4 · Cited by 72
The magic bullet: Niclosamide
Jiang, H., Li, A. M., & Ye, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004978 · Cited by 69
NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity
Wang, Y., Zhou, X., Lei, Y., Chu, Y., Yu, X., Tong, Q., Zhu, T., Yu, H., Fang, S., Li, G., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215884 · Cited by 67
All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation
Persaud, S. D., Park, S. W., Ishigami‐Yuasa, M., Koyano‐Nakagawa, N., Kagechika, H., & Wei, L. (2016) · Scientific Reports · doi:10.1038/srep22396 · Cited by 67
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
Arriazu, E., Pippa, R., & Odero, M. D. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00078 · Cited by 66
From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
Ciccone, M., Călin, G. A., & Perrotti, D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00021 · Cited by 62
Self-citation
Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways
Meng, G., Wang, W., Chai, K., YANG, S., Li, F., & JIANG, K. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2814 · Cited by 62
How I treat atypical chronic myeloid leukemia
Gotlib, J. R. (2016) · Blood · doi:10.1182/blood-2016-08-693630 · Cited by 63
Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies
Acuña‐Hidalgo, R., Deriziotis, P., Steehouwer, M., Gilissen, C., Graham, S. A., van Dam, S., Hoover-Fong, J. E., Telegrafi, A. B., Destrèe, A., Śmigiel, R. S., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006683 · Cited by 59
Metformin prevents the pathological browning of subcutaneous white adipose tissue
Auger, C., Knuth, C. M., Abdullahi, A., Samadi, O., Parousis, A., & Jeschke, M. G. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.011 · Cited by 63
FTY720 for cancer therapy (Review)
Zhang, L., Wang, H., Ji, X., Cong, Z., Zhu, J., & Zhou, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2765 · Cited by 61
Role of protein phosphatases PP1, PP2A, PP4 and Cdc14 in the DNA damage response
Ramos, F., Villoria, M. T., Alonso‐Rodríguez, E., & Clemente‐Blanco, A. (2019) · Cell Stress · doi:10.15698/cst2019.03.178 · Cited by 61
Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways
Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L. N., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3488 · Cited by 59
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
Remmerie, M., & Janssens, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00462 · Cited by 60
First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines
Ramalingam, S., Gediya, L. K., Kwegyir‐Afful, A. K., Ramamurthy, V. P., Purushottamachar, P., Mbatia, H. W., & Njar, V. C. O. (2014) · Oncotarget · doi:10.18632/oncotarget.1528 · Cited by 58
Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response
Yen, Y., Chien, M., Wu, P., Ho, C.-C., Ho, C.-T., Huang, K. C., Chiang, S., Chao, K., Chen, W. T., & Hung, S. (2021) · Nature Communications · doi:10.1038/s41467-021-27620-x · Cited by 61
PP2A-Mediated Anticancer Therapy
Chen, W., Wang, Z., Jiang, C., & Ding, Y. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/675429 · Cited by 59
Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway
Fan, Y., Chen, L., Wang, J., Yao, Q., & Wan, J. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.09.029 · Cited by 56
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model
Bhardwaj, A., Singh, S., Srivastava, S. K., Arora, S., Hyde, S. J., Andrews, J., Grizzle, W. E., & Singh, A. P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.141 · Cited by 57
Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
Liu, P., Xiang, Y., Liu, X., Zhang, T., Yang, R., Chen, S., Xu, L., Yu, Q., Zhao, H., Zhang, L., et al. (2019) · Molecules · doi:10.3390/molecules24030647 · Cited by 56
Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer
Saggam, A., Tillu, G. S., Dixit, S., Chavan, P., Borse, S., Joshi, K., & Patwardhan, B. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112759 · Cited by 55
PRG-1 Regulates Synaptic Plasticity via Intracellular PP2A/β1-Integrin Signaling
Liu, X., Huai, J., Endle, H., Schlüter, L., Fan, W., Li, Y., Richers, S., Yurugi, H., Rajalingam, K., Ji, H., et al. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.06.019 · Cited by 54
Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium
Hsu, A. H., Lum, M. A., Shim, K.-S., Frederick, P. J., Morrison, C. D., Chen, B., Lele, S. M., Sheinin, Y. M., Daikoku, T., Dey, S. K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.067 · Cited by 53
Network Pharmacology-Based Dissection of the Anti-diabetic Mechanism of Lobelia chinensis
Ge, Q., Chen, L., Yuan, Y., Liu, L., Feng, F., Lv, P., Ma, S., Chen, K., & Yao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00347 · Cited by 57
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C. L., Kahl, R. G. S., Flanagan, H. M., Panicker, N., Mashkani, B., Don, A. S., Morris, J. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10167 · Cited by 49
Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo
Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50
Modulation of VEGF receptor 2 signaling by protein phosphatases
Corti, F., & Simons, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.022 · Cited by 50
Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP 2A strikes back
Westermarck, J. K. (2018) · FEBS Journal · doi:10.1111/febs.14617 · Cited by 52
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential
Hung, M.-H., Chen, Y.-L., Chu, P.-Y., Shih, C.-T., Yu, H.-C., Tai, W.-T., Shiau, C.-W., & Chen, K.-F. (2016) · Oncogene · doi:10.1038/onc.2016.21 · Cited by 48
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
Soderstrom, K., Soliman, E., & Dross, R. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00720 · Cited by 52
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation
Ho, W. S., Sizdahkhani, S., Hao, S., Song, H., Seldomridge, A. N., Tandle, A. T., Maric, D., Kramp, T. R., Lu, R. O., Heiss, J. D., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.035 · Cited by 49
Advances in treatment formulations for acute myeloid leukemia
Briot, T., Roger, E., Thépot, S., & Lagarce, F. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.040 · Cited by 52
Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease
Dou, X., Xia, Y., Chen, J., Qian, Y., Li, S., Zhang, X., & Song, Z. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12765 · Cited by 50
Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells
Rahman, M. M., Rumzhum, N. N., Hansbro, P. M., Morris, J. C., Clark, A. R., Verrills, N. M., & Ammit, A. J. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.009 · Cited by 48
Striatins contain a noncanonical coiled coil that binds protein phosphatase 2A A subunit to form a 2:2 heterotetrameric core of striatin-interacting phosphatase and kinase (STRIPAK) complex
Chen, C., Shi, Z., Zhang, W., Chen, M., He, F., Zhang, Z., Wang, Y., Feng, M., Wang, W., Zhao, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529297 · Cited by 47
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A
Zonta, F., Pagano, M. A., Trentin, L., Tibaldi, E. V., Frezzato, F., Trimarco, V., Facco, M., Zagotto, G., Pavan, V., Ribaudo, G., et al. (2015) · Blood · doi:10.1182/blood-2014-12-619155 · Cited by 47
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells
Kaur, A., Denisova, O. V., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S. U., Raheem, O., Haapasalo, H. K., Eriksson, J., Chalmers, A. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1134 · Cited by 47
Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses
Wu, S., Wen, Y.-C., Ku, C., Yang, Y.-C., Chow, J., Yang, S.-F., Lee, W.-J., & Chien, M. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0557-2 · Cited by 47
Jak-STAT3 pathway triggers DICER1 for proteasomal degradation by ubiquitin ligase complex of CUL4A DCAF1 to promote colon cancer development
Ren, W., Shen, S., Sun, Z., Shu, P., Shen, X., Bu, C., Ai, F., Zhang, X., Tang, A., Tian, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.055 · Cited by 46
Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease
Theendakara, V. P., Bredesen, D. E., & Rao, R. V. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.002 · Cited by 45
PP2Ac/STRN4 negatively regulates STING-type I IFN signaling in tumor-associated macrophages
Ho, W. S., Mondal, I., Xu, B., Das, O., Sun, R., Chiou, P., Cai, X., Tahmasebinia, F., McFadden, E., Wu, C. Y.-J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162139 · Cited by 45
KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway
Zhao, L., Zhang, D., Shen, Q. “., Jin, M., Lin, Z., Ma, H., Huang, S., Zhou, P., Wu, G., & Zhang, T. (2018) · Oncogene · doi:10.1038/s41388-018-0493-8 · Cited by 45

Authors: Perrotti, D., & Neviani, P.
Affiliations: The Ohio State University (US)
Corresponding author: Perrotti, Danilo
ORCID: Perrotti, Danilo
Neviani, Paolo
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2013-05
Volume: 14
Issue: 6
Pages: e229-e238
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(12)70558-2
PMC: PMC3913484
OpenAlex: W1987474302
Cited by: 400
References: 103
Citations by year: 2026: 13 · 2025: 17 · 2024: 16 · 2023: 33 · 2022: 31 · 2021: 26 · 2020: 33 · 2019: 35 · 2018: 29 · 2017: 37 · 2016: 62 · 2015: 29 · 2014: 28 · 2013: 11
FWCI: 3.99
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P50CA140158, R01CA163800, R01CA095512, P30CA016058)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: protein phosphatase 2A, tumour suppressor, cancer therapy, fingolimod, oncogenic kinase, serine/threonine phosphatase, chronic myeloid leukemia, therapeutic target
MeSH terms: Animals, Antineoplastic Agents, Enzyme Activation, Humans, Neoplasms, Drug Design, Signal Transduction, Enzyme Activators, Protein Phosphatase 2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Protein phosphatase 2A: a target for anticancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks